Gaseous Microemboli in a Pediatric Bypass Circuit with an Unprimed Venous Line: An In Vitro Study
Miniaturizing cardiopulmonary bypass (CPB) circuits to reduce hemodilution and allogenic blood product administration is common in cardiac surgery.
Clinical Efficacy of Two-Phase Leukocyte Filtration in High-Risk Patients Undergoing Coronary Revascularization with Cardiopulmonary Bypass
The purpose of this study was to investigate the clinical outcome, inflammatory response and myocardial function in high-risk patients undergoing three different leukocyte depletion strategies.
Effects of Platelet-Rich Plasma on BMSCs Differentiation Into SC in Vitro
To explore effect of platelet-rich plasma (PRP) on rabbit BMSCs differentiation into SC in vitro and to detect secretory function of the differentiated cells.
Blood Utilization at a Level I Trauma Center: Is This as Good as it Gets?
Recognition of the adverse effects of allogeneic blood resulted in the decreased use of red blood cell (RBC) transfusion in surgical practice in the 1990s.
Effects of Platelet-Rich Plasma on the Quality of Repair of Mechanically Induced Core Lesions in Equine Superficial Digital Flexor Tendons: A Placebo-Controlled Experimental Study
A placebo-controlled experimental trial was performed to test the hypothesis that a single intratendinous PRP treatment enhances the quality of tendon repair, as evidenced by improved biochemical, biomechanical, and histological tissue properties.
ZymoGenetics Submits Citizen Petition to FDA Requesting Removal of Bovine Thrombin from Market in the Interest of Patient Safety
ZymoGenetics, Inc. (NASDAQ:ZGEN), announced today the submission of a Citizen Petition to the U.S. Food and Drug Administration (FDA) requesting that the FDA remove Thrombin-JMI® Thrombin, topical (bovine origin) from the market in the interest of patient safety. The Citizen Petition is prompted by recent reports of serious or fatal bleeding-related adverse events in surgical patients exposed to bovine (cattle-derived) thrombin.
Hetastarch Increases the Risk of Bleeding Complications in Patients After Off-Pump Coronary Bypass Surgery: A Randomized Clinical Trial
Hetastarch is an artificial colloid widely used intraoperatively in fluid-replacement regimens. Previous studies have found that the intraoperative administration of hetastarch may increase the risk of postoperative bleeding in patients who undergo coronary artery bypass graft surgery with cardiopulmonary bypass.
Relationships Among Haemoglobin Level, Packed Red Cell Transfusion and Clinical Outcomes in Patients After Cardiac Surgery
To identify associations among haemoglobin (Hb) concentrations, blood transfusions, and clinical outcomes in patients after cardiac surgery, especially in those who undergo valve replacement or bypass surgery.
Perioperative Handling of Patients on Antiplatelet Therapy with Need for Surgery
The widespread use of metal stents and drug-eluting stents has shown the extent to which patients with unstable coronary perfusion depend on antiplatelet drugs, and how their risk of late thrombosis depends on the long-term use of agents such as clopidogrel.
The STS and ICEBP: What is the ICEBP’s Role in the Registry Business? (Video)
Doland Likosky discusses the ICEBP's role is setting up an independant perfusion registry (29 minutes).
Patient’s Own Blood Heals (Video)
Some doctors are finding that one of the best healing agents is already inside our own bodies (3 minutes).